BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24569060)

  • 1. Authors' response: The role of risedronate in osteopenia in Crohn's disease.
    van Bodegraven AA; Witte BI; Lips P;
    Gut; 2015 Jan; 64(1):185-6. PubMed ID: 24569060
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of risedronate in osteopenia in Crohn's disease.
    Buchan A; Manuel A
    Gut; 2015 Jan; 64(1):185. PubMed ID: 24304669
    [No Abstract]   [Full Text] [Related]  

  • 3. What is the role for bisphosphonates in IBD?
    Bernstein CN; Targownik LE; Leslie WD
    Gut; 2014 Sep; 63(9):1369-70. PubMed ID: 24221457
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I; Siffledeen J; Siminoski K; McQueen B; Fedorak RN
    J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risedronate improves bone mineral density in Crohn's disease: a complementary mechanism.
    Namazi H
    J Crohns Colitis; 2012 Jul; 6(6):734. PubMed ID: 22483568
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
    Siffledeen JS; Fedorak RN; Siminoski K; Jen H; Vaudan E; Abraham N; Steinhart H; Greenberg G
    Clin Gastroenterol Hepatol; 2005 Feb; 3(2):122-32. PubMed ID: 15704046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Course of Bone Metabolism Disorders in Patients with Inflammatory Bowel Disease: A 5-Year Prospective Study.
    Casals-Seoane F; Chaparro M; Maté J; Gisbert JP
    Inflamm Bowel Dis; 2016 Aug; 22(8):1929-36. PubMed ID: 27135482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation.
    Bakker SF; Dik VK; Witte BI; Lips P; Roos JC; Van Bodegraven AA
    J Crohns Colitis; 2013 Jun; 7(5):377-84. PubMed ID: 22749232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiresorptive treatment after proximal femur fracture].
    Muñoz VL; Roger DR; Valle MB; García LL
    Aten Primaria; 2005 Nov; 36(8):467. PubMed ID: 16287563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Osteoporosis management in general practice. Preventing spontaneous bone fractures].
    MMW Fortschr Med; 2010 Jul; 152(25-27):54-5. PubMed ID: 20672666
    [No Abstract]   [Full Text] [Related]  

  • 12. Weekly risedronate in kidney transplant patients with osteopenia.
    Torregrosa JV; Fuster D; Pedroso S; Diekmann F; Campistol JM; Rubí S; Oppenheimer F
    Transpl Int; 2007 Aug; 20(8):708-11. PubMed ID: 17555530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
    Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
    J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the increase in osteoporosis prevention a result of the audit?
    Naunton M
    Clin Neurol Neurosurg; 2006 Oct; 108(7):718-9. PubMed ID: 16621242
    [No Abstract]   [Full Text] [Related]  

  • 15. Fracture prevention in postmenopausal women.
    Mosekilde L; Vestergaard P; Langdahl B
    Clin Evid; 2006 Jun; (15):1543-60. PubMed ID: 16973058
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
    Ringe JD; Faber H; Farahmand P; Dorst A
    Rheumatol Int; 2006 Mar; 26(5):427-31. PubMed ID: 16001181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease.
    Yurci A; Kalkan AO; Ozbakir O; Karaman A; Torun E; Kula M; Baskol M; Gursoy S; Yucesoy M; Bayram F
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1206-12. PubMed ID: 21971374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs for postmenopausal osteoporosis.
    Treat Guidel Med Lett; 2011 Nov; 9(111):67-74. PubMed ID: 22033166
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT.
    Vanlint SJ; Ried K
    Maturitas; 2012 Jan; 71(1):44-8. PubMed ID: 22078660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis in older people: a tale of two studies (and three treatments).
    Troen BR
    J Am Geriatr Soc; 2006 May; 54(5):853-5. PubMed ID: 16696755
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.